On 6th March 2023, AstraZeneca (AZ) announced that a mid-stage trial of its cancer medicine Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated positive outcomes across multiple HER2-expressing advanced solid tumors in heavily pre-treated individuals.
There is an ongoing trial named DESTINY-PanTumor02 Phase-II trial, which is evaluating the efficacy and safety of Enhertu (trastuzumab deruxtecan) in those with locally advanced or metastatic earlier treated solid tumors that are not a recipient of curative therapy, including ovarian, pancreatic, cervical, and rare cancers.
According to Cristian Messacesi, AZ`s chief medical officer and oncology chief development officer, "The medication Enhertu has already shown its potential to enhance results for those with HER2-targetable lung, breast, and gastric cancers, and these considerable initial outcomes in some other tumor setting with significant unmet necessity are quite encouraging."
About Enhertu (fam-trastuzumab deruxtecan-nxki):
Formulated as a HER2-directed antibody and topoisomerase inhibitor conjugate, the medication Enhertu (fam-trastuzumab deruxtecan-nxki) is supplied for injection: 100 mg lyophilized powder in a single-dose vial. This medicinal product is an antibody-drug conjugate composed of 3 different components. Enhertu 100 mg injection is designed to carry cancer-combating drug to cells that have Trop-2 proteins. Certain unhealthy cells typically have a higher level of Trop-2 proteins.
This antibody-drug conjugate is approved for the treatment of patients with certain different types of cancers:
- HR+/HER2- Metastatic Breast Cancer
- Advanced Bladder Cancer
- Metastatic Triple-Negative Breast cancer
The proposed dose of enhertu 100 mg is administered into the vein through an intravenous (IV) line by a health specialist. The medicine is given one time every 3 weeks (21-day treatment cycle).
Reference:
